Eri Fukaya

Eri Fukaya

Auto-generated profile, based on publicly available information

Eri Fukaya

Division of Vascular Surgery, Stanford University School of Medicine, Palo Alto, CA, USA

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 June 2021 in Circulation Research
Verified
Journal Article
Closed access
PDF file
RBRichard A. Baylis
Richard A. Baylis
NSNicholas L. Smith
Nicholas L. Smith
DKDerek Klarin
Derek Klarin
EFEri Fukaya
Eri Fukaya
Venous disease is a term that broadly covers both venous thromboembolic disease and chronic venous disease. The basic pathophysiology of venous thromboembolism and chronic venous disease differ as venous thromboembolism results from an imbalance of hemostasis and thrombosis while chronic venous disease occurs in the setting of tissue damage because of prolonged venous hypertension. Both diseases are common and account for significant mortality and morbidity, respectively, and collectively make up a large health care burden. Despite both diseases having well-characterized environmental components, it has been known for decades that family history is an important risk factor, implicating a genetic element to a patient’s risk. Our understanding of the pathogenesis of these diseases has greatly benefited from an expansion of population genetic studies from pioneering familial studies to large genome-wide association studies; we now have multiple risk loci for each venous disease. In this review, we will highlight the current state of knowledge on the epidemiology and genetics of venous thromboembolism and chronic venous disease and directions for future research.

11 April 2023 in Journal of Vascular Surgery: Venous and Lymphatic Disorders
Verified
Journal Article
Closed access
AAAnand Athavale
Anand Athavale
MTMai Thao
Mai Thao
VSViviane S. Sassaki
Viviane S. Sassaki
MLMatthew Lewis
Matthew Lewis
VCVenita Chandra
Venita Chandra
EFEri Fukaya
Eri Fukaya

1 June 2024 in Arteriosclerosis, Thrombosis, and Vascular Biology
Verified
Journal Article
Closed access
AAAnand Athavale
Anand Athavale
EFEri Fukaya
Eri Fukaya
NLNicholas J. Leeper
Nicholas J. Leeper

20 June 2023 in JVS-Vascular Insights
Verified
Journal Article
Open access
AAAnand Athavale
Anand Athavale
JBJonathan Baier
Jonathan Baier
ERElsie Ross
Elsie Ross
EFEri Fukaya
Eri Fukaya
Health care providers and recipients have been using artificial intelligence and its subfields, such as natural language processing and machine learning technologies, in the form of search engines to obtain medical information for some time now. Although a search engine returns a ranked list of webpages in response to a query and allows the user to obtain information from those links directly, ChatGPT has elevated the interface between humans with artificial intelligence by attempting to provide relevant information in a human-like textual conversation. This technology is being adopted rapidly and has enormous potential to impact various aspects of health care, including patient education, research, scientific writing, pre-visit/post-visit queries, documentation assistance, and more. The objective of this study is to assess whether chatbots could assist with answering patient questions and electronic health record inbox management. We devised two questionnaires: (1) administrative and non-complex medical questions (based on actual inbox questions); and (2) complex medical questions on the topic of chronic venous disease. We graded the performance of publicly available chatbots regarding their potential to assist with electronic health record inbox management. The study was graded by an internist and a vascular medicine specialist independently. On administrative and non-complex medical questions, ChatGPT 4.0 performed better than ChatGPT 3.5. ChatGPT 4.0 received a grade of 1 on all the questions: 20 of 20 (100%). ChatGPT 3.5 received a grade of 1 on 14 of 20 questions (70%), grade 2 on 4 of 16 questions (20%), grade 3 on 0 questions (0%), and grade 4 on 2/20 questions (10%). On complex medical questions, ChatGPT 4.0 performed the best. ChatGPT 4.0 received a grade of 1 on 15 of 20 questions (75%), grade 2 on 2 of 20 questions (10%), grade 3 on 2 of 20 questions (10%), and grade 4 on 1 of 20 questions (5%). ChatGPT 3.5 received a grade of 1 on 9 of 20 questions (45%), grade 2 on 4 of 20 questions (20%), grade 3 on 4 of 20 questions (20%), and grade 4 on 3 of 20 questions (15%). Clinical Camel received a grade of 1 on 0 of 20 questions (0%), grade 2 on 5 of 20 questions (25%), grade 3 on 5 of 20 questions (25%), and grade 4 on 10 of 20 questions (50%). Based on our interactions with ChatGPT regarding the topic of chronic venous disease, it is plausible that in the future, this technology may be used to assist with electronic health record inbox management and offload medical staff. However, for this technology to receive regulatory approval to be used for that purpose, it will require extensive supervised training by subject experts, have guardrails to prevent "hallucinations" and maintain confidentiality, and prove that it can perform at a level comparable to (if not better than) humans. (JVS-Vascular Insights 2023;1:100019.).

1 November 2021 in Cardiology Clinics
Verified
Journal Article
Closed access
TATom Alsaigh
Tom Alsaigh
EFEri Fukaya
Eri Fukaya

20 June 2023 in Medical Clinics of North America
Verified
Journal Article
Closed access
VSViviane Seki Sassaki
Viviane Seki Sassaki
EFEri Fukaya
Eri Fukaya